PE20010489A1 - Nueva forma cristalina de la sal disodica del acido n-[4-[2-[2-amino-4,7-dihidro-4-oxo-3h-pirrolo[2,3-d]-pirimidin-5-il)etil]benzoil]-l-glutamico y procedimientos para el mismo - Google Patents
Nueva forma cristalina de la sal disodica del acido n-[4-[2-[2-amino-4,7-dihidro-4-oxo-3h-pirrolo[2,3-d]-pirimidin-5-il)etil]benzoil]-l-glutamico y procedimientos para el mismoInfo
- Publication number
- PE20010489A1 PE20010489A1 PE2000000850A PE0008502000A PE20010489A1 PE 20010489 A1 PE20010489 A1 PE 20010489A1 PE 2000000850 A PE2000000850 A PE 2000000850A PE 0008502000 A PE0008502000 A PE 0008502000A PE 20010489 A1 PE20010489 A1 PE 20010489A1
- Authority
- PE
- Peru
- Prior art keywords
- ethyl
- salt
- benzoil
- pyrrolo
- pyrimidin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION DE UN COMPUESTO DE FORMULA I QUE COMPRENDE HACER REACCIONAR PIRROLO [2,3-d]PIRIMIDINA SUSTITUIDA EN LA POSICION 5 DE FORMULA III CON HIDROXIDO DE SODIO; R ES UN GRUPO PROTECTOR DE CARBOXI TAL COMO ESTER METILICO O ETILICO. TAMBIEN SE REFIERE A LA SAL ACIDA DEL ACIDO N-[4-[2-(2-AMINO-4,7-DIHIDRO-4-OXO-3H-PIRROLO[2,3-d]PIRIMIDIN-5-IL)ETIL]BENZOIL]-L-GLUTAMICO QUE SE CARACTERIZA POR SU DIAGRAMA DE DIFRACCION DE RAYOS X. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION QUE COMPRENDE LA CRISTALIZACION DE LA SAL DISODICA DEL COMPUESTO I EN UN DISOLVENTE ADECUADO, AJUSTANDO EL pH DE 7,5 A 8,0 DE LA SOLUCION ACUOSA. EL CRISTAL DEL COMPUESTO ES UN INHIBIDOR DE DIVERSAS ENZIMAS QUE REQUIERENPUEDE SER UTIL PARA EL TRATAMIENTO DE CANCER DE MESOTELIOMA
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15025499P | 1999-08-23 | 1999-08-23 | |
US18496400P | 2000-02-25 | 2000-02-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20010489A1 true PE20010489A1 (es) | 2001-04-27 |
Family
ID=26847471
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2000000850A PE20010489A1 (es) | 1999-08-23 | 2000-08-22 | Nueva forma cristalina de la sal disodica del acido n-[4-[2-[2-amino-4,7-dihidro-4-oxo-3h-pirrolo[2,3-d]-pirimidin-5-il)etil]benzoil]-l-glutamico y procedimientos para el mismo |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1212325A2 (es) |
AU (1) | AU6890800A (es) |
CO (1) | CO5200767A1 (es) |
PE (1) | PE20010489A1 (es) |
WO (1) | WO2001014379A2 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1259513E (pt) * | 2000-02-25 | 2004-02-27 | Lilly Co Eli | Nova forma cristalina de acido n-¬4- ¬2-amino-4,7-dihidro -4-oxo-3h-pirrolo¬2,3-d|pirimidin-5-il)etil| - benzoil|-l-glutamico e processo para a sua obtencao |
US20050208139A1 (en) | 2004-03-22 | 2005-09-22 | Ascend Therapeutics, Inc. | Chemically stable compositions of 4-hydroxy tamoxifen |
US8088919B2 (en) * | 2006-08-14 | 2012-01-03 | Sicor Inc. | Crystalline forms of pemetrexed diacid and processes for the preparation thereof |
JP2008543975A (ja) | 2006-08-14 | 2008-12-04 | シコール インコーポレイティド | 高度に純粋なペメトレキセド二酸およびその調製方法 |
KR101083230B1 (ko) | 2006-08-14 | 2011-11-11 | 시코르, 인크. | 페메트렉세드 이산의 동결 건조된 약학적 허용염의 제조 방법 |
US7994180B2 (en) | 2006-08-14 | 2011-08-09 | Sicor Inc. | Processes for preparing intermediates of pemetrexed |
EP2129674A2 (en) * | 2007-04-03 | 2009-12-09 | Dr. Reddy's Laboratories Ltd. | Solid forms of pemetrexed |
CN101417998B (zh) | 2007-10-24 | 2012-10-24 | 重庆医药工业研究院有限责任公司 | 一种培美曲塞盐的纯化方法 |
EP2072518A1 (en) * | 2007-12-23 | 2009-06-24 | Sun Pharma Advanced Research Company Limited | Stable Amorphous Form of Pemextred Disodium |
KR101760657B1 (ko) * | 2008-06-06 | 2017-07-24 | 베링거 인겔하임 인터내셔날 게엠베하 | 약제학적 병용물 |
EP2334685A4 (en) * | 2008-09-08 | 2011-10-26 | Reddys Lab Ltd Dr | AMORPHOUS PEMETREXED DISODIUM |
WO2010030598A2 (en) * | 2008-09-11 | 2010-03-18 | Dr. Reddy's Laboratories Limited | Pharmaceutical formulations comprising pemetrexed |
CN101684121B (zh) | 2008-09-22 | 2013-04-03 | 重庆医药工业研究院有限责任公司 | 培美曲塞二酸的新晶型及其制备方法 |
TW201118098A (en) * | 2009-08-13 | 2011-06-01 | Reddy S Lab Liimited Dr | Processes for preparing pemetrexed |
CN102050825B (zh) * | 2009-11-05 | 2014-12-17 | 上海创诺制药有限公司 | 制备培美曲塞二钠2.5水结晶的方法 |
US9174991B2 (en) | 2009-11-24 | 2015-11-03 | Azad Pharmaceutical Ingredients Ag | Crystalline form of pemetrexed disodium |
WO2012017443A1 (en) * | 2010-08-02 | 2012-02-09 | Neon Laboratories Ltd. | Process for preparation of highly pure dialkyl pemetrexed |
KR101308767B1 (ko) | 2011-01-20 | 2013-12-31 | 에스티팜 주식회사 | 고 순도 페메트렉세드 디에틸 에스테르의 제조방법 및 이 방법을 포함하는 페메트렉세드 이나트륨염의 제조방법 |
EP2675808A4 (en) * | 2011-02-15 | 2014-07-09 | Hetero Research Foundation | PROCESS FOR OBTAINING DISODIUM PEMETREXED |
US9051322B2 (en) | 2011-03-23 | 2015-06-09 | Scinopharm Taiwan, Ltd. | Process for the production of a pemetrexed salt |
JP5826371B2 (ja) * | 2011-03-25 | 2015-12-02 | サイノファーム タイワン リミテッド | ペメトレキセド塩の製造方法 |
NZ705994A (en) * | 2012-10-17 | 2015-08-28 | Shilpa Medicare Ltd | Process for preparing pemetrexed di potassium and its hydrates |
EP2953616A2 (en) | 2013-02-06 | 2015-12-16 | Cipla House | Pemetrexed complexes and pharmaceutical compositions containing pemetrexed complexes |
EP2997031A1 (en) | 2013-05-17 | 2016-03-23 | Instytut Farmaceutyczny | Process for the preparation of high purity amorphous pemetrexed disodium and crystalline forms of n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3- d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid |
WO2015008221A1 (en) | 2013-07-16 | 2015-01-22 | Dr. Reddy’S Laboratories Limited | Novel crystalline forms of pemetrexed tromethamine salts |
NZ630292A (en) | 2013-11-25 | 2015-02-27 | Shilpa Medicare Ltd | Process for crystalline pemetrexed dipotassium salt |
CN103784454B (zh) * | 2014-01-22 | 2015-11-18 | 海南锦瑞制药有限公司 | 一种含有培美曲塞二钠化合物的药物组合物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL135190A (en) * | 1997-09-26 | 2005-03-20 | Lilly Co Eli | Processes and intermediates useful to make antifolates |
-
2000
- 2000-08-15 WO PCT/US2000/020777 patent/WO2001014379A2/en not_active Application Discontinuation
- 2000-08-15 AU AU68908/00A patent/AU6890800A/en not_active Abandoned
- 2000-08-15 EP EP00957261A patent/EP1212325A2/en not_active Withdrawn
- 2000-08-22 PE PE2000000850A patent/PE20010489A1/es not_active Application Discontinuation
- 2000-08-22 CO CO00062633A patent/CO5200767A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CO5200767A1 (es) | 2002-09-27 |
EP1212325A2 (en) | 2002-06-12 |
WO2001014379A2 (en) | 2001-03-01 |
AU6890800A (en) | 2001-03-19 |
WO2001014379A3 (en) | 2001-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20010489A1 (es) | Nueva forma cristalina de la sal disodica del acido n-[4-[2-[2-amino-4,7-dihidro-4-oxo-3h-pirrolo[2,3-d]-pirimidin-5-il)etil]benzoil]-l-glutamico y procedimientos para el mismo | |
ES2674174T3 (es) | Antagonista de LPA1 policíclico y usos del mismo | |
CO5670355A2 (es) | Forma cristalina de sal de calcio de acido bis [(e)-7-[4-(4-fluorofenil)-6-isopropil-2-[metil(metilsulfonil)amino]pirimidin-5-il](3r,5s)-3,5-dihidroxihept-6-enoico | |
AR044773A1 (es) | Proceso quimico para la fabricacion de la sal calcica del acido (e) -7- ( 4-(-fluorofenil) 6-isopropil-2-(metil(metilsulfonil)amino)pirimidin-5-il)(3r,5s)-3,5-dihidroxihept-6-enoico | |
CA2397450A1 (en) | Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid | |
NO2015020I1 (no) | Ceritinib, 5-klor-N-5-metyl-4-(piperidin-4-yl)-2-[(propan-2-yl)oksy]fenyl-N-[2-(propan-2-sulfonyl)fenyl]pyrimidine-2,4-diamin, eller et farmasøytisk akseptabelt salt derav | |
AR100790A2 (es) | COMPUESTOS HETEROCÍCLICOS, ACTIVOS COMO INHIBIDORES DE b-LACTAMAS | |
PT89769B (pt) | Processo para a preparacao de derivados do acido 3-alcenil-1-azabiciclo-{3,2,0}hept-2-eno-2-carboxilico | |
PT1140860E (pt) | Compostos de pirimidina | |
BR9916790A (pt) | Uso de um composto, composto, processo para amanufatura do mesmo, composição farmacêtica, e,método para produzir um efeito de dano vascularem um animal de sangue quente | |
PE20011228A1 (es) | Derivados de piridopirimidina o iminopirimidina utiles para el tratamiento de enfermedades neurodegenerativas | |
MX9303441A (es) | Procedimiento para la preparacion de acido clavulanico. | |
PE108099A1 (es) | Acidos 5-alquil-2-arilaminofenilaceticos y sus derivados | |
UY28577A1 (es) | Proceso químico e intermedios | |
PE20090550A1 (es) | Composicion farmaceutica solida que comprende un derivado de bencimidazol y un agente de control de ph | |
PE20110147A1 (es) | Composicion y proceso - 356 | |
ES2394850T3 (es) | Inhibidor de cinesina mitótica | |
NZ610765A (en) | Method for the preparation of high-purity pharmaceutical intermediates | |
CS203135B2 (en) | Method of producing racemic or optically active pyrimido/1,2a/heterocyclic compounds | |
PT84819B (pt) | Processo para a preparacao de compostos 2-piridil-penem | |
DE69124330T2 (de) | Optisch aktive Thienotriazolodiazepin-Verbindungen | |
ES2132672T3 (es) | Nuevas sales de acido 2-((2,6-diclorofenil)amino)fenil-acetoxiacetico con cationes basicos organicos. | |
FR2892721B1 (fr) | Nouveau procede de preparation de sels d'acides et d'ammonium quaternaires | |
CA2500485A1 (en) | Acyl derivatives of 5-(2-(4-(1,2 benzisothiazole-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one having neuroleptic activity | |
DK0428132T3 (da) | Pradimicinderivater |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |